Falling Insulin Requirement Linked to Placental Dysfunction

Share this content:
Falling Insulin Requirement Linked to Placental Dysfunction
Falling Insulin Requirement Linked to Placental Dysfunction

WEDNESDAY, Aug. 16, 2017 (HealthDay News) -- For pregnant women with pre-existing diabetes, falling insulin requirement (FIR) is associated with altered expression of placental antiangiogenic factors and preeclampsia, according to a study published online Aug. 10 in Diabetes Care.

Suja Padmanabhan, M.B.B.S., M.P.H., from Westmead Hospital in Sydney, and colleagues conducted a multicenter cohort study involving 158 pregnant women with pre-existing diabetes (41 with type 1 and 117 with type 2). Thirty-two women had FIR of ≥15 percent from the peak total daily dose after 20 weeks of gestation and were considered case subjects. The primary outcome was a composite of clinical markers of placental dysfunction.

The researchers found that FIR ≥15 percent correlated with an increased risk of the composite primary outcome (odds ratio, 4.38) and preeclampsia (odds ratio, 6.76), and was more common among women with type 1 diabetes (36.6 versus 14.5 percent). Women with FIR ≥15 percent had modestly elevated creatinine; no difference was seen in hemoglobin A1c. Among women with FIR at 25, 30, and 36 weeks, the ratio of soluble fms-like tyrosine kinase 1 to placental growth factor was significantly higher, with differences maintained among those who developed preeclampsia. No difference was seen in placental hormones between the groups.

"FIR is an important clinical sign, among women with pre-existing diabetes, that should alert the clinician to investigate underlying placental dysfunction," the authors write.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »